Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL)

Children's Oncology Group (COG)


Clinical Trial

Offered by: Nemours
Locations: Delaware Valley, Jacksonville, FL, Orlando, FL, Pensacola, FL

Trial Name

A Phase III Study if Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition

What is the trial about?

To find out if adding Lestaurtinib to standard therapy for intermediate and high risk infants with ALL will result in better treatment outcomes than standard chemotherapy alone.

Who can participate?

< 366 days of age at the time of diagnosis; for neonates in the first month of life, patients must be > 36 weeks gestational age at the time of diagnosis.

What is involved?

Length of study is 2 years. In addition to standard induction treatment, the following tests and procedures will be performed: Blood Samples for Lestaurtinib Analysis and Minimal Residual Disease (MRD) and Resistance Mechanisms.

Contact Nemours Clinical Trials

Trial Name: A Phase III Study if Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition

COG#: AALL0631

Contact Information

(800) 354-5690
clinicaltrials@nemours.org